UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2563-2574

2016

Volltextzugriff (PDF)

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Volltextzugriff (PDF)

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Clinical cancer research, 2007-03, Vol.13 (5), p.1576-1583

2007

Volltextzugriff (PDF)

Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Journal of medicinal chemistry, 2021-11, Vol.64 (21), p.16213-16241

2021

Volltextzugriff (PDF)

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Clinical cancer research, 2017-02, Vol.23 (4), p.1025-1035

2017

Volltextzugriff (PDF)

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

Oncogene, 2003-08, Vol.22 (32), p.4953-4963

2003

Volltextzugriff (PDF)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

HemaSphere, 2023-08, Vol.7 (S3), p.e68516d0-n/a

2023

Volltextzugriff (PDF)

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

Current topics in medicinal chemistry, 2005-01, Vol.5 (2), p.215

2005

Volltextzugriff (PDF)

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Proceedings of the National Academy of Sciences - PNAS, 2000-08, Vol.97 (16), p.8991-8996

2000

Volltextzugriff (PDF)

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.441-444

2006

Volltextzugriff (PDF)

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Blood, 2018-11, Vol.132 (Supplement 1), p.3505-3505

2018

Volltextzugriff (PDF)

ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S245-S245

2023

Volltextzugriff (PDF)

Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S145-S145

2023

Volltextzugriff (PDF)

POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S154-S154

2023

Volltextzugriff (PDF)

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3047-3047

2015

Volltextzugriff (PDF)

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Cancer immunology research, 2020-03, Vol.8 (3_Supplement), p.B55-B55

2020

Volltextzugriff (PDF)

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

The Journal of biological chemistry, 1996-02, Vol.271 (6), p.2921-2928

1996

Volltextzugriff (PDF)

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1677-1677

2014

Volltextzugriff (PDF)

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Diabetes (New York, N.Y.), 1994-11, Vol.43 (11), p.1297

1994

Volltextzugriff (PDF)

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2515-2515

2010

Volltextzugriff (PDF)

Evolution of Rodent Lysozymes: Isolation and Sequence of the Rat Lysozyme Genes

Molecular phylogenetics and evolution, 1993-03, Vol.2 (1), p.65-75

1993

Volltextzugriff (PDF)

The cloning and characterization of a novel 53kDa substrate of the insulin receptor tyrosine kinase family

Yeh, Tammie Chimui

1997

Volltextzugriff (PDF)

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK

Cancer, 2006, p.83-132

2006

Volltextzugriff (PDF)

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study

Canadian Medical Association journal (CMAJ), 2022-04, Vol.194 (14), p.E513

2022

Volltextzugriff (PDF)

Conference Proceedings—Improving the Quality and Efficiency of Emergency Care Across the Continuum: A Systems Approach

Academic emergency medicine, 2011-06, Vol.18 (6), p.655-661

2011

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(32)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(17)
Animals
(8)
Covid-19
(5)
Oncology
(5)
Pediatrics
(5)
Severe Acute Respiratory Syndrome Coronavirus 2
(5)
Cancer
(4)
Chemistry, Medicinal
(4)
Child
(4)
Children
(4)
Coronaviruses
(4)
Infections
(4)
Mice
(4)
Pharmacology & Pharmacy
(4)
Sars-Cov-2
(4)
Xenograft Model Antitumor Assays
(4)
Antineoplastic Agents - Pharmacology
(3)
Biochemistry & Molecular Biology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Evolution of Rodent Lysozymes: Isolation and Sequence of the Rat Lysozyme Genes

The cloning and characterization of a novel 53kDa substrate of the insulin receptor tyrosine kinase family

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study

Conference Proceedings—Improving the Quality and Efficiency of Emergency Care Across the Continuum: A Systems Approach

Suchergebnisse filtern